AbbVie will pay up to $2.2 billion to develop Danish drugmaker Gubra's obesity drug. AI takes center stage at HIMSS ...

South Africa's competition watchdog is investigating drugmakers Novo Nordisk and Sanofi over possible anti-competitive ...

AbbVie's strategic move into the obesity market through a partnership with Gubra A/S shows potential but won't impact revenue ...

Over 90 nutritionists have hit back at Ozempic maker Novo Nordisk's project to update the Nova classification for ...

Pfizer's Q4/24 results showed significant improvements, with total revenue up 21.9% YoY and adjusted diluted EPS increasing ...

Stifel Nicolaus cut shares of Novo Nordisk A/S (NYSE:NVO – Free Report) from a buy rating to a hold rating in a report issued ...

California made a bold announcement that it would manufacture a state-branded, low-cost insulin. It still is not here.

Novo Nordisk has signed a deal with AI-driven protein design company Gensaic to develop tissue-targeted therapies for ...

Drugmaker AbbVie has agreed to license a weight-loss drug currently in development from Gubra for up to about $2.2 billion, marking its entry into the obesity treatment market.

A licensing deal with Denmark’s Gubra gives the immunology giant control of an experimental therapy that could compete with ...

During a hearing, representatives for the Newsom administration said they could not provide a timeline for when ...

Anthropic on Monday closed its latest funding round at a $61.5 billion post-money valuation, the company confirmed to CNBC.